CAR-T cells

Overview

Chimeric antigen receptor T (CAR-T) cell therapy is an adoptive immunotherapy in which a patient's own T lymphocytes are genetically engineered to express synthetic surface receptors — chimeric antigen receptors (CARs) — that redirect cytotoxic killing toward tumor cells expressing a specified antigen. A CAR construct typically fuses an extracellular antigen-binding domain (most commonly a single-chain variable fragment, or scFv, derived from a monoclonal antibody) to intracellular signaling domains such as CD3ζ and co-stimulatory modules (e.g., 4-1BB or CD28), enabling T-cell activation independent of MHC presentation. Following ex vivo expansion and reinfusion, CAR-T cells can traffic to disease sites, recognize target antigen, and mount a sustained cytotoxic response.

CAR-T cell therapies have demonstrated landmark clinical efficacy in B-cell malignancies — including B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma — establishing the platform as a paradigm shift in oncology. Research frontiers now address key limitations including manufacturing complexity and delay, T-cell exhaustion, limited persistence, immunosuppression within the tumor microenvironment, and poor efficacy against solid tumors. Expanding the reach of CAR-T platforms beyond hematologic cancers, and into infectious diseases and fibrotic conditions, is an active area of translational investigation.

Focus of Latest Publications

Recent publications reflect a broad and rapidly evolving research landscape for CAR-T cells, spanning target antigen engineering, in vivo manufacture, metabolic optimization, and novel disease applications.

Hematologic Malignancies and Persistence A 2026 study published in Blood (PMID 41990270) examined single-day, nonactivated CAR-T cells armed with IL-18 (IL18), demonstrating that this abbreviated manufacturing protocol establishes a durable, stem-like T-cell state associated with enhanced persistence. The finding is clinically significant because conventional multi-day activation protocols can accelerate T-cell differentiation and exhaustion, which limits long-term antitumor surveillance. The study underscores how cytokine co-stimulation — particularly with proinflammatory cytokines such as IL-18 — can reprogram CAR-T cell fate toward more potent, self-renewing phenotypes.

In Vivo CAR-T Engineering A breakthrough study highlighted in Cancer Discovery (PMID 41940795) reported the first in vivo engineering of CAR-T cells at therapeutically relevant levels against both hematologic and solid cancers, circumventing the need for ex vivo cell manufacturing entirely. This approach, if validated in humans, could dramatically reduce the cost and logistical burden currently associated with personalized CAR-T products.

Solid Tumor Applications and Overcoming the tumor microenvironment Multiple recent studies address the long-standing challenge of extending CAR-T efficacy to solid tumors. Research published in Science Translational Medicine (PMID 41984929) demonstrated that on-demand overexpression of the glucose transporter GLUT3 augments CAR-T cell metabolic fitness and antitumor efficacy in preclinical glioblastoma (GBM) models, directly addressing the metabolic hostility imposed by the tumor microenvironment. Separately, a MedComm study (PMID 41930329) reported non-viral, cytokine-inducible CAR-T cells targeting fibroblast activation protein alpha (Fap-α) in GBM, achieving potent antitumor activity through locus-specific genomic integration, offering a non-viral manufacturing alternative. An in vivo CRISPR screen (Molecular Therapy, PMID 41935953) identified target genes whose knockout improves CAR-T function in solid tumor models, revealing potential combinatorial strategies involving pathways connected to T-cell exhaustion and signaling nodes such as STAT3 and MCL1.

Novel Antigen Targeting A study in Biochemical and Biophysical Research Communications (PMID 41936239) described the engineering of optimized single-chain variable fragments (scFvs) targeting CD99 — a surface marker overexpressed in Ewing sarcoma and other carcinomas — establishing rational design principles for scFv length optimization and supporting their application in CAR-T cell development. Research in Cell Communication and Signaling (PMID 41964005) explored CAR-T cells as one of several therapeutic modalities targeting B7-H3 (CD276), an immune checkpoint ligand enriched in the tumor microenvironment and on tumor-derived exosomes, in potential synergy with PD-1/PD-L1 checkpoint blockade.

Infectious Disease Applications Expanding beyond oncology, a study in Science Advances (PMID 42030390) deployed CAR-T cells — including constructs targeting PD-1 (programmed cell death 1), designated bPD1-CAR and nbPD1-CAR — to reduce the HIV reservoir in infected humanized mouse models. The authors highlighted the unique capacity of CAR-T cells to infiltrate tissues and eliminate latently infected cells, opening a new therapeutic avenue for chronic viral diseases previously considered intractable.

Non-Oncological and Senescence-Related Applications A review in Kidney International (PMID 41581730) discussed the emerging use of CAR-T cells alongside CRISPR-Cas gene editing and adeno-associated virus (AAV)-mediated delivery to target cellular senescence in diabetic kidney disease, representing an early conceptual expansion of CAR-T platforms into chronic metabolic and fibrotic conditions.

Real-Time Tracking and Manufacturing Quality Two studies addressed the monitoring and characterization of CAR-T products. Research published in Nanoscale Horizons (PMID 41589415) used nanobubble-based contrast-enhanced ultrasound to visualize CAR-T cell trafficking in tumor-bearing mice in vivo, enabling noninvasive spatial tracking of therapeutic cells post-infusion. A study in Molecular Therapy: Advances (PMID 42147443) introduced a single-cell multi-omics assay enabling simultaneous measurement of vector copy number (VCN) and protein expression within CAR-T products, providing critical quality control data relevant to safety and potency. Finally, a review in Advanced Drug Delivery Reviews (PMID 41707940) situated CAR-T cell development within the broader landscape of microfluidic transfection systems, highlighting the role of these technologies in enabling scalable, personalized gene delivery for therapeutic manufacturing.

Key Publications

• Jun A single-cell multi-omics assay for simultaneous measurement of vector copy number and protein expression in CAR T cells. (Molecular therapy. Advances, 2026, PMID 42147443): "Chimeric antigen receptor T cell (CAR T) immunotherapies have transformed cancer treatment."
• Jun Development of single chain antibodies for targeting Ewing sarcoma surface marker CD99. (Biochemical and biophysical research communications, 2026, PMID 41936239): "These findings establish a rational design principle for optimizing CD99-targeting scFvs and support the potential application of the 15-mer scFv in CAR-T cell development and in targeting other CD99-overexpressing carcinomas."
• May Researchers Engineer CAR T Cells In Vivo against Multiple Malignancies. (Cancer discovery, 2026, PMID 41940795): "This study demonstrates the first in vivo engineering of CAR T cells at a therapeutic level for both hematologic and solid cancers."
• Apr Targeting PD-1+ T cells with chimeric antigen receptors to reduce the HIV reservoir. (Science advances, 2026, PMID 42030390): "The unique ability of chimeric antigen receptor (CAR) T cells to infiltrate tissues is revolutionizing our perspectives for tackling severe, refractory and otherwise untreatable diseases."
• Apr Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence. (Blood, 2026, PMID 41990270): "Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell malignancies, yet challenges including manufacturing delays, T-cell exhaustion, and limited persistence impede broader clinical success."
• Apr On-demand GLUT3 expression augments CAR T cell metabolic fitness and antitumor efficacy in preclinical models of glioblastoma. (Science translational medicine, 2026, PMID 41984929): "The clinical success of chimeric antigen receptor T cell (CAR T cell) therapy in hematologic malignancies has prompted its application for refractory solid tumors, including glioblastoma (GBM)."
• Apr B7-H3 (CD276) in exosome biogenesis and the tumor microenvironment: a new therapeutic nexus. (Cell communication and signaling : CCS, 2026, PMID 41964005): "Additionally, we discuss strategies for therapeutically targeting exosomal B7-H3, including monoclonal and bispecific antibodies, CAR-T cells, and exosome inhibitors, as well as their potential synergy with immunotherapies."
• Apr In vivo tracking of CAR-T cells in tumors via nanobubble-based contrast enhanced ultrasound. (Nanoscale horizons, 2026, PMID 41589415): "Utilizing this method, we found that CAR-T cells can be visualized after injection into both tumor-bearing and non-tumor bearing mice."
• Apr Targeting cellular senescence in diabetic kidney disease: potential of regenerative, cell-based therapies and other senotherapeutic approaches. (Kidney international, 2026, PMID 41581730): "Other advanced technologies, including chimeric antigen receptor T cell, clustered regularly interspaced short palindromic repeats gene editing, and adeno-associated virus-mediated gene delivery, offer unique opportunities to expand the DKD armamentarium to reduce cellular senescence abundance and chronic inflammation."
• Apr Non-Viral Cytokine-Inducible SH2 Containing Protein Locus-Specific Integrated Fibroblast Activation Protein Alpha-Targeting Chimeric Antigen Receptor T Cells Achieve Potent Antitumor Efficacy in Glioblastoma. (MedComm, 2026, PMID 41930329): "Chimeric antigen receptor T (CAR-T) cells have been used to treat patients with glioblastoma (GBM) in clinical trial settings by targeting GBM-associated antigens."